key: cord-0914443-bfgas778 authors: Pennarossa, Georgia; Ghiringhelli, Matteo; Gandolfi, Fulvio; Brevini, Tiziana A. L. title: Creation of a Bioengineered Ovary: Isolation of Female Germline Stem Cells for the Repopulation of a Decellularized Ovarian Bioscaffold date: 2021-02-19 journal: Next Generation Culture Platforms for Reliable In Vitro Models DOI: 10.1007/978-1-0716-1246-0_9 sha: 82e0311fa4ae4ece942cc176229ccdcdc4cfcba3 doc_id: 914443 cord_uid: bfgas778 Ovarian failure is the most common cause of infertility and affects about 1% of young women. One innovative strategy to restore ovarian function may be represented by the development of a bioprosthetic ovary, obtained through the combination of tissue engineering and regenerative medicine. We here describe the two main steps required for bioengineering the ovary and for its ex vivo functional reassembling. The first step aims at producing a 3D bioscaffold, which mimics the natural ovarian milieu in vitro. This is obtained with a whole organ decellularization technique that allows the maintenance of microarchitecture and biological signals of the original tissue. The second step involves the use of magnetic activated cell sorting (MACS) to isolate purified female germline stem cells (FGSCs). These cells are able to differentiate in ovarian adult mature cells, when subjected to specific stimuli, and can be used them to repopulate ovarian decellularized bioscaffolds. The combination of the two techniques represents a powerful tool for in vitro recreation of a bioengineered ovary that may constitute a promising solution for hormone and fertility function restoring. In addition, the procedures here described allow for the creation of a suitable 3D platform with useful applications both in toxicological and transplantation studies. Infertility is a growing issue in modern society. According to the World Health Organization, it represents the fifth highest serious global disability, with an alarming incidence of one out of 1000 women, under the age of 30, rising to 1.0-1.5% in women younger than 40 years [1, 2] . Ovary dysfunction and premature ovarian insufficiency (POI) represent the main causes of infertility and can occur as a result of an inherited condition, de novo mutation or from insults to the ovarian tissue, including viral infections and environmental factors [2] [3] [4] . Furthermore, therapy-induced ovarian failure due to chemotherapy and radiation treatments, can cause oocyte and/or surrounding support cell apoptosis in cancer survivors [5] [6] [7] [8] [9] . To date, several approaches have been developed and used in clinics to restore ovarian functions, including oocyte, embryo and ovarian tissue cryopreservation [10] [11] [12] [13] [14] [15] [16] [17] [18] . However, since these procedures are largely devoted to cancer patients, the high risk of malignant cell reintroduction pose a severe limit to their use in clinical practices [19, 20] . Development of a bioengineered ovary may provide a safe option in fertility restoration for all patients, including cancer survivors. We here describe the two main steps required for the ex vivo creation of a bioprosthetic ovary and its functional assembling. The first step is based on a decellularization technique that produces an extracellular matrix (ECM)-based3D-scaffold. The second one allows the repopulation of the decellularized bioscaffold in order to create a functional in vitro bioengineered ovary. To date, many reports in the literature describe the regeneration in vitro of different organs using decellularized scaffolds [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . However, limited studies have been performed in the reproductive system, and, more specifically, in the ovarian tissue [31, 32] . Indeed, the majority of decellularization protocols was specifically developed for ovarian tissue fragments and cortical slides [33] [34] [35] , while the use of an entire ovary was limited to the bovine [32] , the mouse [36, 37] , and the porcine [38] . The decellularization protocol here described leads to the creation of a whole-ovary 3D bioscaffold preserves intact microarchitecture as well as ECM structures and components [38] (Fig. 1) . It combines the use of physical and chemical methods to remove cellular components and generate 3D ovarian bioscaffold that recreates in vitro the complex in vivo ovarian milieu, facilitating the necessary interactions between cells and their surroundings and ensuring a correct cell growth, differentiation and function [39] . The obtained whole-ovary bioscaffold can be repopulated with a single cell type or with different ovarian cell populations, including fibroblasts, stromal and granulosa cells, or follicles. Among the several cell types present in the ovary, female germline stem cells (FGSCs) can be a promising candidate. Indeed, when subjected to specific stimuli, these cells are able to differentiate in ovarian adult mature cells and generate fully functional oocytes [40, 41] . We here describe the isolation of FGSCs by using magnetic activated cell sorting (MACS). Obtained cells can be stably maintained in culture, undergo mitotic division and steadily express germline and pluripotency-related genes (Fig. 2) . Moreover, when used for the recellularization of decellularized ovary, FGSCs are able to rapidly migrate into the bioscaffold, adhering and colonizing the ECM within 24 h, and, during the subsequent days of culture, they increase in number and form cluster-like structures (Fig. 3) . Overall, the method here reported is simple, fast and highly efficient and paves the way for a possible in vitro ovarian tissue reconstruction that may result advantageous for a general improvement of reproductive technologies, and possible future application to organ transplantation for hormone and fertility function restoring. Prepare all solutions immediately before use (unless indicated otherwise). 1. Porcine ovaries collected from a local slaughterhouse. 2. 500 mL plastic bottle. 3. Ice container. 6. Antibiotic/Antimycotic Solution. 1. 50 mL centrifuge polypropylene tubes. 2. Water bath. 3. Orbital shaker. 4. 500 mL plastic or glass bottle. All the procedures described below must be performed under sterile conditions. Instruments touching or in connection to the ovary have to be sterilized. Cell isolation must be carried out under laminar a flow hood and cell cultures have to be maintained at 37 C during their handling using thermostatically controlled stages. 3.1 Ovary Collection 1. Collect ovaries from gilts weighing approximately 120 kg. 2. Separate ovaries from fallopian tubes by cutting them with surgical scissor. 3. Transfer ovaries in cold sterile PBS containing antibiotic-antimycotic solution (5 mL/500 mL) and transport them to the laboratory using ice container. 1. Wash ovary in fresh PBS, completely remove the PBS, place ovary in 50 mL tube and store organ at À80 C for at least 24 h (see Note 2, Fig. 4 ). 2. Thaw whole-ovary at 37 C in a water bath for 30 min. 3. Transfer whole-ovary in a bottle containing 500 mL of 0.5% SDS. Place the bottle onto an orbital shaker at 200 rpm and incubate for 3 h at room temperature. 4. Remove SDS solution from the bottle containing the wholeovary and add 500 mL of 1% Triton X-100. Incubate wholeovary over-night at room temperature in 1% Triton X-100, using an orbital shaker at 200 rpm. 2. Wash ovary twice in 50 mL of fresh sterile PBS at room temperature. 3. Place ovary into a 100 mm sterile petri dish and cut ovarian cortex into small pieces (approximately cubes of 1-2 mm 2 ) using a surgical scalpel. 4. Wash fragments four times in sterile PBS at room temperature. 10. Dissociate to single-cell suspension by pipetting up and down using a 10 mL serological pipette. 11. Pass cell suspension through a 30-μm nylon mesh filter to remove cell clumps which may clog the column (see Note 4). 12. Count cells using a counting chamber under an optical microscope at room temperature. Calculate the volume of medium needed to resuspend cells in order to obtain 10 7 cells in 80μL (see Note 5). 13. Centrifuge cell suspension at 300  g for 5 min. Aspirate supernatant completely and resuspend cell pellet in 80μL of precooled FGSC culture medium per 10 7 total cells (see Note 6). 14. Add 20μL of Anti-SSEA-4 MicroBeads per 10 7 total cells (see Note 7) . Mix well and incubate for 15 min at +4 C (see Note 8). 15. Wash cells by adding 2 mL of FGSC culture medium and centrifuge at 300  g for 5 min. Aspirate supernatant and resuspend in 500μL of fresh precooled FGSC culture medium. 16 . Place column in the magnetic field of a MACS Separator and prepare column by rinsing 3 mL of precooled FGSC culture medium. 17. Apply cell suspension onto the column and collect flowthrough containing unlabeled cells (see Note 9). Wash column tree time with 3 mL of FGSC culture medium (see Note 10). 18. Remove column from the separator and place it on a 50 mL collection tube. Pipette 5 mL of FGCS culture medium onto the column. Immediately flush out the magnetically labeled cells by firmly pushing the plunger into the column (see Note 11). 19. Centrifuge cell suspension at 300  g for 5 min. Aspirate supernatant completely and resuspend cell pellet in of FGSC culture medium and plate cells in gelatin precoated 4-well dish (see Subheading 3.3, steps 1 and 8) and culture the incubator under aseptic conditions with 5% CO 2 at 37 C. 1. FGCS culture medium can be stored at +4 C a maximum of 10 days. 2. Intact ovaries can be stored at À80 C for long time periods without causing matrix alteration. 3. The obtained bioscaffold can be either directly used for histological analysis or sterilized for cell repopulation. Its sterilization procedure can be performed using 70% ethanol and 2% antibiotic in sterile H 2 O for 30 min at room temperature. Before cell repopulation, wash bioscaffold extensively with PBS and 4% Antibiotic at room temperature using an orbital shaker at 200 rpm. 4. Moisten filter with culture medium before use. 5. The formula to be used depends on the specific type of chamber. Cells/μL ¼ Average number of cells per small grid  chamber multiplication factor  dilution. 6. Work fast, keep cells cold, and use precooled solutions. This will prevent capping of antibodies on the cell surface and nonspecific cell labelling. 7. The microbead volume here reported is necessary for up to 10 7 cells. When working with fewer cells, use the same quantity. When working with higher cell numbers, scale up the volumes accordingly. 8. The incubation temperature and period are fundamental for specific cell labeling. Higher temperatures and/or longer incubation times may lead to nonspecific cell labelling. 9. FGCS are labelled cells. The unlabeled ones, collected in this step, can be discarded or cultured for negative control. 10 . Add medium only when the column reservoir is empty. 11. To increase the purity of SSEA-4+ cells, the eluted fraction can be enriched with a new second column, repeating the magnetic separation procedure. Update on primary ovarian insufficiency Genetics of primary ovarian insufficiency: new developments and opportunities Scientific principles of regenerative medicine and their application in the female reproductive system Regenerative medicine for the treatment of reproductive system disorders: current and potential options Cancer statistics Predicting age of ovarian failure after radiation to a field that includes the ovaries Optimizing reproductive outcome in children and young people with cancer Medical and psychosocial aspects of fertility after cancer Fertility preservation in girls during childhood: is it feasible, efficient and safe and to whom should it be proposed? Improving cryopreservation systems Cryopreservation of human embryos and its contribution to in vitro fertilization success rates Human embryo cryopreservation-methods, timing, and other considerations for optimizing an embryo cryopreservation program Pregnancy after human oocyte cryopreservation In: Textbook of Oncofertility research and practice Oocyte freezing Female gamete preservation Cryopreservation of female reproductive potential Engineering a bioprosthetic ovary for fertility and hormone restoration Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe The behavior of cardiac progenitor cells on macroporous pericardium-derived scaffolds Enhanced reseeding of decellularized rodent lungs with mouse embryonic stem cells Development of liver Decellularized extracellular matrix bioink for three-dimensional cell printing-based liver tissue engineering Decellularized kidney scaffold-mediated renal regeneration Muscle extracellular matrix scaffold is a multipotent environment Dynamic decellularization and cross-linking of rat tracheal matrix Experimental orthotopic transplantation of a tissue-engineered oesophagus in rats Urinary tissue engineering: challenges and opportunities Decellularization of human internal mammary artery: biomechanical properties and histopathological evaluation A new material for tissue engineered vagina reconstruction: acellular porcine vagina matrix A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice Initiation of puberty in mice following decellularized ovary transplant Initial steps in reconstruction of the human ovary: survival of pre-antral stage follicles in a decellularized human ovarian scaffold Xenogeneic Decellularized scaffold: a novel platform for ovary regeneration Decellularized human ovarian scaffold based on a sodium lauryl ester sulfate (SLES)-treated protocol, as a natural three-dimensional scaffold for construction of bioengineered ovaries Evaluating two ovarian decellularization methods in three species Decellularization of the mouse ovary: comparison of different scaffold generation protocols for future ovarian bioengineering Whole-ovary decellularization generates an effective 3D bioscaffold for ovarian bioengineering Decellularization strategies for regenerative medicine: from processing techniques to applications The existence and potential of germline stem cells in the adult mammalian ovary Initial characterisation of adult human ovarian cell populations isolated by DDX4 expression and aldehyde dehydrogenase activity This work was funded by Carraresi Foundation and PSR2017. The Laboratory of Biomedical Embryology is member of the COST Action CA16119 In vitro 3-D total cell guidance and fitness (Cell-Fit) and of the Inter-COST Actions Task-Force on Covid-19.